记者丨朱艺艺 编辑丨季媛媛 一纸公告，揭开了两家上市药企的专利纷争。 华东医药公告摘录 这场诉讼的核心，直指华东医药曾经的独家重磅品种——年销售额曾突破30亿元的百令胶囊，而发酵冬 虫夏草菌粉即为百令胶囊的核心原料。 不过，随着2024年1月，佐力药业的百令胶囊以同名同方药获批，华东医药一直独占百令胶囊的局面被 打破，在百令系列领域，两家公司几乎"二分天下"。 对于该案进展，12月16日，华东医药相关人士告诉21世纪经济报道记者，公司将向最高人民法院提起上 诉，至于本次涉案金额增加，"增加部分为中美华东新增维权合理开支费用"。 同日，佐力药业相关人士则向21世纪经济报道记者回应，"公司始终尊重知识产权，控股子公司珠峰药 业取得百令片药品注册批件及生产、销售百令片的行为符合国家法律法规的规定，对于华东医药后续再 上诉，我们会积极面对，也有信心胜诉"。 华东医药一审败诉 两家上市药企对簿公堂，核心纷争是发酵冬虫夏草菌粉及其制剂百令片的发明专利权归属。 早在2024年1月，华东医药全资子公司中美华东一纸诉状，将佐力药业控股子公司珠峰药业、青海珠峰 冬虫夏草原料有限公司（简称"珠峰原料"）、杭州华东武林大药房有限公司 ...

Core Viewpoint - The article discusses the patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, focusing on the core ingredient of the Bailing capsule, which has historically generated significant sales revenue for Huadong Medicine [5][8]. Group 1: Patent Dispute Details - The lawsuit centers on the patent rights of fermented Cordyceps sinensis powder, which is the main ingredient in the Bailing capsule, previously a unique product for Huadong Medicine with annual sales exceeding 3 billion yuan [8][12]. - Huadong Medicine filed a lawsuit against Zhaoli Pharmaceutical and its subsidiaries, claiming infringement of its patent rights and seeking approximately 1.11 billion yuan in damages [11][12]. - The Zhejiang High Court ruled against Huadong Medicine in the first instance, dismissing all claims and ordering it to bear over 590,000 yuan in court fees [13][14]. Group 2: Market Competition - The competition between Huadong Medicine and Zhaoli Pharmaceutical is intensifying, with both companies nearly splitting the market for Bailing products [8][17]. - Huadong Medicine's Bailing capsule was a major product, achieving sales of over 3 billion yuan in 2019, but faced a decline in sales due to price reductions after being included in the medical insurance directory [17][18]. - Zhaoli Pharmaceutical, through acquisitions, has positioned itself in the Bailing market, with its Bailing tablet generating revenue of 2.02 billion yuan in 2023, down 21.23% from the previous year due to competitive pressures [18][19]. Group 3: Future Outlook - Zhaoli Pharmaceutical aims to grow its Bailing series into a 1 billion yuan product line, with expectations of increased revenue as the product gains market traction following its recent approval [19]. - As of December 16, 2023, Huadong Medicine's market capitalization was approximately 69.1 billion yuan, while Zhaoli Pharmaceutical's was around 11.9 billion yuan, indicating a significant disparity in market valuation [19].

一纸公告，揭开了两家上市药企的专利纷争。 12月15日，上市药企华东医药（000963.SZ）公告称，全资子公司杭州中美华东制药有限公司(简称"中美华东")收到浙江省高级人民法院（简称"浙江省高 院"）《民事判决书》((2023) 浙知民初3号)，围绕其与佐力药业（300181.SZ）控股子公司青海珠峰冬虫夏草药业有限公司（简称"珠峰药业"）关于发酵冬虫 夏草菌粉的发明专利权纠纷，在经过2024年4月、6月的两次公开开庭后，法院驳回了中美华东的全部诉讼请求，该案涉案金额约1.1139亿元(较首次披露暂 计金额增加10600元)。 这场诉讼的核心，直指华东医药曾经的独家重磅品种——年销售额曾突破30亿元的百令胶囊，而发酵冬虫夏草菌粉即为百令胶囊的核心原料。 两家上市药企对簿公堂，核心纷争是发酵冬虫夏草菌粉及其制剂百令片的发明专利权归属。 早在2024年1月，华东医药全资子公司中美华东一纸诉状，将佐力药业控股子公司珠峰药业、青海珠峰冬虫夏草原料有限公司（简称"珠峰原料"）、杭州华 东武林大药房有限公司（简称"华东药房"）告上了浙江省高院，认为三位被告侵犯了其发酵冬虫夏草菌粉的发明专利权，要求其停止侵权行为，并赔偿 ...